Vertex Hepatitis C Drug Study Shows Good Results
May 24, 2006
On Monday, Vertex Pharmaceuticals reported good results for its hepatitis C drug candidate in all of the subjects tested in a mid-stage clinical trial. Among the 12 subjects taking the firm's drug VX-950 in combination with ribavirin and pegylated interferon alfa-2a, all had their virus reduced to undetectable levels after 28 days of treatment. After 12 more weeks, 11 patients continued to have no detectable HCV.
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.